An experimental mRNA cancer vaccine from BioNTech failed to meet one of two primary endpoints in a pivotal trial, adding to the obstacles faced by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.